Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of aliskiren plus hydrochlorothiazide (HCTZ)
in patients who do not achieve controlled blood pressure levels after treatment with another
specified antihypertensive medication. There was an optional study extension for the first
eligible 60 patients who wanted to participate that contains the triple therapy with
amlodipine 5 mg and aliskiren 300 mg plus HCTZ 25 mg.